Ultragenyx Pharmaceutical Inc. (RARE): Emil D Kakkis , President & CEO of Ultragenyx Pharmaceutical Inc. sold 20,000 shares on Jul 15, 2016. The Insider selling transaction was reported by the company on Jul 19, 2016 to the Securities and Exchange Commission. The shares were sold at $50.97 per share for a total value of $1,016,908.50 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 21, 2016, Sunil Agarwal (Chief Medical Officer) sold 650 shares at $54.16 per share price.On May 18, 2016, Emil D Kakkis (President & CEO) sold 20,000 shares at $60.74 per share price.Also, On Dec 18, 2015, Theodore Alan Huizenga (Controller and PAO) sold 1,500 shares at $110.55 per share price.On Dec 14, 2015, Shalini Sharp (CFO & Senior Vice President) sold 12,000 shares at $101.60 per share price.
Ultragenyx Pharmaceutical Inc: On Monday, Jul 18, 2016 heightened volatility was witnessed in Ultragenyx Pharmaceutical Inc which led to swings in the share price. The shares opened for trading at $53.46 and hit $54.39 on the upside , eventually ending the session at $53.53, with a gain of 0.68% or 0.36 points. The heightened volatility saw the trading volume jump to 7,00,260 shares. The 52-week high of the share price is $137.05 and the company has a market cap of $2,089 M . The 52-week low of the share price is at $46.52.
Company has been under the radar of several Street Analysts.Ultragenyx Pharmaceutical Inc is Initiated by Piper Jaffray to Overweight and the brokerage firm has set the Price Target at $70. The Rating was issued on Jul 7, 2016.Ultragenyx Pharmaceutical Inc is Initiated by BofA/Merrill to Buy. The Rating was issued on Jun 28, 2016.Ultragenyx Pharmaceutical Inc is Reiterated by Wedbush to Outperform while Lowering the Price Target of the company shares to $ 92 from a previous price target of $99 . The Rating was issued on May 10, 2016.
Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification acquisition development and commercialization of products for the treatment of rare and ultra-rare diseases with a focus on serious debilitating genetic diseases. Its pipeline consists of two product categories: biologics including a monoclonal antibody and enzyme replacement therapies and small-molecule substrate replacement therapies. Its products are KRN23 (UX023) rhGUS (UX003) rhPPCA (UX004) Triheptanoin (UX007) and SA-ER (UX001). KRN23 is a fully human monoclonal antibody administered via subcutaneous injection. rhGUS is an intravenous (IV) enzyme replacement therapy for the treatment of mucopolysaccharidosis 7. rhPPCA is an enzyme replacement therapy for galactosialidosis. Triheptanoin is a medium odd-chain triglyceride of seven-carbon fatty acids. SA-ER is for the treatment of hereditary inclusion body myopathy (HIBM).